Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
Lexicon Pharmaceuticals announced the presentation of additional Phase 2b study data (PROGRESS) on pilavapadin, supporting the selection of the 10 mg dose for Phase 3 development in diabetic peripheral neuropathic pain (DPNP). The data demonstrate a nominally significant reduction in average pain with good tolerability. The company also shared prec…